TargetMol

Procarbazine hydrochloride

Product Code:
 
TAR-T1488
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T1488-100mg100mg£103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1488-1mL1 mL * 10 mM (in DMSO)£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T1488-200mg200mg£121.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Procarbazine Hydrochloride is the hydrochloride salt of a methylhydrazine derivative with antineoplastic and mutagenic activities. Although the exact mode of cytotoxicity has not been elucidated, procarbazine, after metabolic activation, appears to inhibit the trans-methylation of methionine into transfer RNA (t-RNA), thereby preventing protein synthesis and consequently DNA and RNA synthesis. This agent may also undergo auto-oxidation, resulting in the formation of cytotoxic free radicals which damage DNA through an alkylation reaction.
CAS:
366-70-1
Formula:
C12H20ClN3O
Molecular Weight:
257.76
Pathway:
Cell Cycle/Checkpoint; DNA Damage/DNA Repair
Purity:
0.98
SMILES:
Cl.CNNCc1ccc(cc1)C(=O)NC(C)C
Target:
DNA Alkylator/Crosslinker; DNA/RNA Synthesis

References

1. Ogawa K, et al. Mutat Res,2003, 539(1-2), 145-155. 2. Suzuki T, et al. Mutat Res,1999, 444(2), 269-281. 3. Weissenberg R, et al. Arch Androl,2002, 48(2), 91-100. 4. Holt A, et al. J Pharm Pharmacol,1995, 47(10), 837-845. 5. Pletsa V, et al. Carcinogenesis,1997, 18(11), 2191-2196.